Presented inside a, b and cContemporary Clinical Dentistry | Jan-Mar 2014 | Vol 5 | Challenge
Presented inside a, b and cContemporary Clinical Dentistry | Jan-Mar 2014 | Vol five | Challenge 1Javidi, et al.: Zinc oxide nanoparticles as sealer Table 1: Description with the groupsGroups G1 G2 G3 G4 G5 C CCross-sectioning at the CEJ Cross-sectioning at the CEJ Cross-sectioning at the CEJ Cross-sectioning in the CEJ Cross-sectioning in the CEJ Cross-sectioning at the CEJ Intact teeth Approach of preparation Instrumentation to ISO #35 Instrumentation to ISO #35 Instrumentation to ISO #35 Instrumentation to ISO #35 Instrumentation to ISO #35 Instrumentation to ISO #35 No instrumentation External root coverage except for 2-mm at the apex External root coverage except for 2-mm in the apex External root coverage except for 2-mm in the apex External root coverage except for 2-mm in the apex External root coverage except for 2-mm in the apex External root coverage except for 2-mm at the apex Complete coverage of the root surfaces Sealer AH26 ZnO nano-powders (calcined at 500 ) ZnO nano-powders (calcined at 600 ) ZnO nano-powders (calcined at 700 ) ZnO micro-powders No obturation No obturationCEJ: Cemento-Enamel JunctionTable two: Imply and SD (0-7) of apical microleakage of 5 experimental groups as l. min-1. cm H2O-Groups G1 G2 G3 G4 G5 three days soon after obturation 7.75.17 0.72.82 1.17.99 2.52.25 80.2908.64 45 days following obturation 7.65.00 0.72.82 1.42.36 2.40.05 119.6842.88 90 days just after obturation 7.52.03 0.31.50 1.69.68 2.39.05 162.4407.unknown risks involved within the use of ZnO nanopowders as a healthcare material must be deemed to confirm their safety.AcknowledgmentThis study was supported by a grant from the Vice Chancellor of Investigation Council of Mashhad University of Health-related Sciences, Iran.
02-Charalampos_- 200913 16:54 PaginaMini-reviewInside the “fragile” infant: pathophysiology, molecular background, danger things and investigation of neonatal osteopeniaCharalampos Dokos1,two Christos Tsakalidis1 Athanasios Tragiannidis2 Dimitrios Rallis2nd Neonatology Clinic, Papageorgiou Hospital, Healthcare College, Aristotle University of Thessaloniki, Thessaloniki, Greece two nd two Pediatric Clinic, AHEPA Hospital, Healthcare School, Aristotle University of Thessaloniki, Thessaloniki, Greece Address for correspondence: Charalampos Dokos, MD Medical College, Papageorgiou Hospital Aristotle University of Thessaloniki, Thessaloniki, Greece 35797735079 E-mail: dokos1984yahoo.grSummary Current study in bone mineral metabolism reveals a lot of DNMT3 site aspects of osteopenia occurred in premature infants. This assessment examines not just the pathophysiological and molecular mechanisms of newborn osteopenia but additionally the threat variables and investigation. Osteopenia of premature infants has improved incidence among other ailments of prematurity. Identification of threat elements is crucial for monitoring of osteopenia. Some of the risk ALK6 drug factors contain low birth weight, prematurity, long term administration of drugs for instance corticosteroids, methyloxanthines, furosemide, abnormalities in vitamin D metabolism, poor maternal nutritional and mineral uptake etc. Neonatologists, pediatricians and endocrinologists should investigate premature, low birth weight infants that have higher serum alkaline phosphatase and have at the very least one particular risk element.Key WORDS: premature infants; osteopenia; bone metabolism; low birth weight; vitamin D metabolism.birth weight (VLBW), osteopenia is actually a typical cause of pathological fractures. Decreased BMD is often a outcome of either decreased bone mineralization or enhanced bone reabso.